Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other financing activities (2016 - 2024)

Historic Other financing activities for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q4 2024 value amounting to $2.0 million.

  • Ani Pharmaceuticals' Other financing activities changed N/A to $2.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.8 million, marking a year-over-year increase of 4435000.0%. This contributed to the annual value of $17.4 million for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Ani Pharmaceuticals' Other financing activities stood at $2.0 million.
  • Ani Pharmaceuticals' 5-year Other financing activities high stood at $13.6 million for Q4 2021, and its period low was -$690000.0 during Q4 2022.
  • Over the past 4 years, Ani Pharmaceuticals' median Other financing activities value was $203000.0 (recorded in 2022), while the average stood at $1.5 million.
  • Data for Ani Pharmaceuticals' Other financing activities shows a peak YoY increase of 4840000.0% (in 2022) and a maximum YoY decrease of 10506.16% (in 2022) over the last 5 years.
  • Ani Pharmaceuticals' Other financing activities (Quarter) stood at $169000.0 in 2020, then skyrocketed by 7966.27% to $13.6 million in 2021, then tumbled by 105.06% to -$690000.0 in 2022, then skyrocketed by 386.52% to $2.0 million in 2024.
  • Its Other financing activities was $2.0 million in Q4 2024, compared to -$690000.0 in Q4 2022 and $483000.0 in Q3 2022.